Project Engineer - Project Engineering

Regeneron Pharmaceuticals said its drug Pasatru (garetosmab-grts) showed sustained results in adults with fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder that causes bone to grow in muscle and connective tissue. The 84-week data from the Phase 3 OPTIMA trial were presented at the American Society for Bone and Mineral Research annual meeting. From week 56 to week 84, patients on Pasatru had no new abnormal bone lesions, against nine for placebo. New flare-ups numbered one on the 10 mg/kg dose, 14 on the 3 mg/kg dose, and 17 on placebo. The trial enrolled 63 adults. Skin and soft tissue infections rose with dose but all resolved, and no patients stopped treatment because of them. The US Food and Drug Administration recently approved Pasatru. A trial in children and adolescents is planned to begin later this year.

TODAY: President Trump rallies in Syracuse. Commentary. If you are covering President Trump's rally in Syracuse today, please consider this statement from the Republican National Committee: "Kathy Hochul is the worst governor in America and wants to keep New York a high-tax, pro-crime, sanctuary state. New Yorkers are sick of it and fired up to welcome President Trump and Republicans like Bruce Blakeman who will fight for all New Yorkers by standing with law enforcement, lowering costs, and bringing back common sense." - RNC Spokesperson Kristen Cianci Background: President Trump And Republicans Delivered Historic Tax Cuts * The Working Families Tax Cuts saved each New Yorker an average $4,079 in taxes. * New York will see wages increase by up to $8,000 over the next four years. * The expanded SALT cap delivered $32.2 billion in tax savings. * 5% of New York workers benefit from no tax on tips. * Up to 62% of New York workers benefit from no tax on overtime. * 3.3 million seniors in New York benefit from no tax on Social Security. President Trump Is Delivering Major Investments Across New York * President Trump has secured $11.2 trillion in direct foreign investments that are fueling job growth, innovation, and opportunity. * Micron raised its planned U.S. investments to more than $250 billion through 2035 for its new semiconductor manufacturing plant in Clay, New York, fourteen miles from Syracuse. * Anheuser-Busch invested $9 million into its Baldwinsville, New York, brewery near Syracuse to increase production of its alcohol brands. * GlobalFoundries announced $16 billion in investment to increase domestic semiconductor production and advanced packaging capabilities, including at its Malta, New York facility. * IBM announced plans to invest $150 billion into the United States over the next five years, including into its manufacturing plant in Poughkeepsie, New York. * Regeneron invested $2 billion into a new drug manufacturing facility in Saratoga County, creating 1,000 new jobs. * Chobani announced a $1.2 billion investment in a new manufacturing facility in Rome, New York. Thanks To President Trump Violent Crime Has Fallen At Historic Rates * In 2026, in New York, murders fell by 48%, and New York City saw the fewest shootings and murders in recorded history. * Operation Tidal Wave 1.0 arrested two people in Albany, New York, during a fraud investigation that led to the seizure of over 130 illegal firearms. * Operation Tidal Wave 2.0 arrested over 40 people in Albany, New York, in connection with drug distribution and illegal firearms. * Francisco Javier Roman-Bardales, a high-ranking member of MS-13, was charged in the Eastern District of New York for narco-terrorism, racketeering, material support for terrorism, and alien-smuggling conspiracies. * Operation Rotten Apple arrested nearly 2,200 illegal aliens across New York, including murderers, rapists, pedophiles, drug traffickers, and violent criminals. * Operation Salvo arrested 54 people in an immigration enforcement surge in New York following the shooting of a CBP officer; among those arrested are members of transnational gangs responsible for drug and weapon trafficking and human smuggling.

A gene therapy treatment has restored hearing in children born deaf due to inherited OTOF gene variants. In a clinical trial, nine of 12 children with profound deafness gained meaningful hearing after receiving Otarmeni (lunsotogene parvec-cwha), developed by Regeneron. The treatment delivers a working copy of the otoferlin gene directly into the cochlea using a dual AAV1 vector. By 24 weeks, four patients achieved normal to near-normal hearing, whilst four others had mild to moderate hearing loss. Cincinnati Children's Hospital treated two siblings as part of the trial. Three-year-old Abdu went from hearing virtually nothing to normal range hearing within weeks. His one-year-old sister Sumaya also showed dramatic improvement. The therapy addresses OTOF-related congenital deafness, which accounts for approximately 1% of congenital deafness cases. Results were published in The New England Journal of Medicine.